Issue Price
₹51
Per Share
GMP
NIL
Grey Market
Est. Listing
₹51
Expected Price
Min. Application
₹204,000
2 lots × 2000 shares
Incorporated in 2003, Chandra Bhagat Pharma Limited is engaged in the marketing of lifesaving medicines in India such as Cardiovascular, Antineoplastic, Antibiotics and Hormones medicines. They provide pharmaceuticals and special chemical products in the Indian and international market.The company has own sales force and distribution network to work under the brand name and supply products to the Health care center and Hospital. Chandra Bhagat Pharma also deals in import, supply and indenting in Active Pharmaceuticals Ingredients (API) and the intermediate.The company has FDA approval to get formulations manufactured from a contract manufacturer. It has a presence for formulations in some therapeutic categories such as Anesthesia, Cardiovascular, Anti-cancer (Oncology), Pediatrics, Nephrology, Antiviral, Anti-fungal, and Neurology. The warehouses/ storage houses of the company are on lease agreements at Bhiwandi- Thane, Maharashtra.Chandra Bhagat Pharma also exports Pharmaceutical Formulations to other countries like DR Congo, Bolivia and Philippines.Competitive Strengths1. Customer centric and order driven business model2. Relationships with MNCs3. Wide product portfolio including API and pharmaceuticals4. Contract manufacturing facility5. Presence in India and international market
Chandra Bhagat Pharma Ltd proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| Market Maker | 100,000 | — | ₹0.51 Cr | — |
| TOTAL | 2,000,000 | 100.00% | ₹10.20 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | ₹102,000 |
| Retail (Max) | 13 | 26,000 | ₹1,326,000 |
| sNII (Min) | 14 | 28,000 | ₹1,428,000 |
| bNII (Min) | 68 | 136,000 | ₹6,936,000 |
| Particulars | 30-July-19 | 31-Mar-19 | 31-Mar-18 |
|---|---|---|---|
| Revenue from Operations | 3344.50 | 10671.83 | 9773.41 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 24.88 | 62.59 | 103.38 |
| Net Worth | N/A | N/A | N/A |
| Total Assets | 8594.26 | 8285.52 | 5805.76 |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | N/A | N/A | N/A |